While GEM kills bladder cancer cells through apoptosis, it also induces a cytoprotective autophagy involving HMGB1-mediated JNK and ERK activation, and targeting this pathway may improve the anticancer efficacy of gemcitabine against bladder cancer. Here, HMGB1 is linked to urinary bladder carcinoma.